TREM1 blockade has been tried already as a therapeutic option in sepsis animal models using either a chimeric molecule containing the extracellular domain of TREM1 and the Fc portion of a human IgG1 molecule or an antagonistic TREM1 peptide LP17, both of which reduced pro-inflammatory cytokines to sub-lethal levels [34, 38–40]. This evidence concerns the gene TREM1 and Sepsis.